Nanobody based imaging and targeting of ECM in disease and development
AssigneesMassachusetts Institute of Technology, Children's Medical Center Corporation, Whitehead Institute for Biomedical Research
InventorsRichard O. Hynes, Noor Jailkhani, Hidde L. Ploegh, Yushu Joy Xie
Life of this patent
Estimating the term…
Abstract
Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
Claims15
A composition, comprising
- a nanobody which is specific for and binds directly to a diseased state extracellular matrix (ECM) epitope, wherein the diseased state ECM epitope is (i) an epitope in EIIIB domain of fibronectin, or (ii) tenascin C or an epitope of tenascin C, wherein the nanobody is conjugated to an active agent, and wherein the nanobody comprises a complementarity determining region (CDR)1, CDR2 and CDR3 comprising a) SEQ ID NO:
- 19, SEQ ID NO:
- 36, and SEQ ID NO:
- 53, respectively;
- b) SEQ ID NO:
- 25, SEQ ID NO:
- 42, and SEQ ID NO:
- 59, respectively;
- c) SEQ ID NO:
- 26, SEQ ID NO:
- 43, and SEQ ID NO:
- 60, respectively;
- or d) SEQ ID NO:
- 28, SEQ ID NO:
- 45, and SEQ ID NO:
- 62, respectively.
A composition, comprising
- a peptide comprising a sequence set forth in any one of SEQ ID NOs:
- 1-4 or an antigen-binding fragment thereof and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.